PL1606318T3 - Ulepszone białka fuzyjne FC - Google Patents

Ulepszone białka fuzyjne FC

Info

Publication number
PL1606318T3
PL1606318T3 PL04723552T PL04723552T PL1606318T3 PL 1606318 T3 PL1606318 T3 PL 1606318T3 PL 04723552 T PL04723552 T PL 04723552T PL 04723552 T PL04723552 T PL 04723552T PL 1606318 T3 PL1606318 T3 PL 1606318T3
Authority
PL
Poland
Prior art keywords
domain
fusion proteins
improved
ligand
receptor
Prior art date
Application number
PL04723552T
Other languages
English (en)
Inventor
Henning Walczak
Original Assignee
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Apogenix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts, Apogenix Ag filed Critical Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Publication of PL1606318T3 publication Critical patent/PL1606318T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
PL04723552T 2003-03-26 2004-03-26 Ulepszone białka fuzyjne FC PL1606318T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03006949 2003-03-26
EP04723552A EP1606318B1 (en) 2003-03-26 2004-03-26 Improved fc fusion proteins
PCT/EP2004/003239 WO2004085478A2 (en) 2003-03-26 2004-03-26 Improved fc fusion proteins

Publications (1)

Publication Number Publication Date
PL1606318T3 true PL1606318T3 (pl) 2010-01-29

Family

ID=33040920

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04723552T PL1606318T3 (pl) 2003-03-26 2004-03-26 Ulepszone białka fuzyjne FC

Country Status (15)

Country Link
US (2) US8007813B2 (pl)
EP (2) EP1606318B1 (pl)
JP (2) JP2007533595A (pl)
AT (1) ATE438662T1 (pl)
AU (2) AU2004224122A1 (pl)
CA (2) CA2520138C (pl)
CY (1) CY1109536T1 (pl)
DE (1) DE602004022390D1 (pl)
DK (1) DK1606318T3 (pl)
ES (1) ES2327409T3 (pl)
HK (1) HK1077592A1 (pl)
PL (1) PL1606318T3 (pl)
PT (1) PT1606318E (pl)
SI (1) SI1606318T1 (pl)
WO (2) WO2004085478A2 (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
CN101094688B (zh) 2004-09-13 2013-05-01 建新公司 多聚构建体
EP2662088A3 (en) * 2005-02-03 2014-02-19 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
CA2619048A1 (en) 2005-08-15 2007-02-22 The Regents Of The University Of California Vegf-activated fas ligands
US10155816B2 (en) * 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2007070948A1 (en) * 2005-12-20 2007-06-28 Arana Therapeutics Limited Anti-inflammatory dab
CN103232540A (zh) 2006-02-01 2013-08-07 赛法隆澳大利亚控股有限公司 结构域抗体构建体
CN101074261A (zh) * 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
WO2007131652A1 (de) * 2006-05-17 2007-11-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verfahren zum auffinden von antiatherosklerotischen substanzen
DK2101877T3 (da) 2006-12-28 2013-09-23 Deutsches Krebsforsch Neutralisering af virkningen af CD95 til blokering af invasion af glioblastomceller in vivo
CN103897063B (zh) 2007-06-01 2017-04-12 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
ES2524553T3 (es) 2008-06-17 2014-12-10 Apogenix Gmbh Receptores multiméricos de TNF
US20110189194A1 (en) * 2008-07-14 2011-08-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
CN102892778B (zh) 2010-02-19 2018-06-08 列日大学 用于治疗甲型流感病毒诱发的疾病、编码经修饰的Mx蛋白的多核苷酸、蛋白和转基因动物
EP3543257A1 (en) 2010-07-28 2019-09-25 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
HRP20180154T1 (hr) 2010-08-06 2018-03-09 Genzyme Corporation Pripravci vegf antagonista i njihova uporaba
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
US20140370012A1 (en) * 2012-01-27 2014-12-18 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
MX2014014804A (es) * 2012-06-27 2015-02-12 Hoffmann La Roche Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
EP2867253B1 (en) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
EP2874659B1 (en) 2012-07-18 2016-07-13 Apogenix AG Inhibitors of the cd95 signaling pathway for treatment of mds
CA2877989C (en) * 2012-07-18 2021-05-25 Apogenix Gmbh Shortened cd95-fc variants
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
WO2015158810A1 (en) * 2014-04-17 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides and uses thereof for reducing cd95-mediated cell motility
WO2016118577A1 (en) * 2015-01-22 2016-07-28 Medimmune, Llc Thymosin-beta-four fusion proteins
BR112017023646A2 (pt) 2015-05-04 2018-07-17 Apogenix Ag proteínas agonistas de receptor de cd40 de cadeia simples
SI3325011T1 (sl) 2015-07-24 2021-02-26 Gliknik Inc. Fuzijski proteini humanih proteinskih fragmentov za tvorbo pravilnih multimeriziranih imunoglobulin FC sestavkov s povečanim vezanjem komplementa
EP3364995B1 (en) 2015-10-23 2021-08-04 Apogenix AG Single-chain cd27-receptor agonist proteins
JP6873119B2 (ja) 2015-10-23 2021-05-19 アポジェニックス アーゲー 一本鎖ｌｉｇｈｔ受容体アゴニストタンパク質
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
EP3551647A4 (en) 2016-12-09 2021-01-13 Gliknik Inc. MANUFACTURING OPTIMIZATION OF GL-2045, A MULTIMERIZING STRADOMER
IL266988B2 (en) 2016-12-09 2024-11-01 Gliknik Inc Methods of treating inflammatory disorders with multivalent fc compounds
CA3134144A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
KR20220122639A (ko) 2019-11-27 2022-09-02 미스트 쎄라퓨틱스, 엘엘씨 조절제를 이용한 종양 반응성 t 세포 조성물의 제조 방법
WO2021174208A1 (en) 2020-02-27 2021-09-02 Myst Therapeutics, Llc Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
GB202016058D0 (en) 2020-10-09 2020-11-25 Ucl Business Ltd Therapeautic treatment
CN115197328B (zh) * 2021-04-09 2025-05-16 北京大学第一医院 一种可清除体内免疫球蛋白A的重组融合蛋白酶及其制备方法和在治疗IgA肾病中的应用
WO2026044087A1 (en) 2024-08-21 2026-02-26 Shape Therapeutics Inc. Increased cellular stability for aav production
WO2026073032A1 (en) 2024-09-27 2026-04-02 Shape Therapeutics Inc. Constructs for improved aav production

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5830469A (en) 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
DE4447484C2 (de) 1994-04-08 1997-07-17 Deutsches Krebsforsch Mittel zur Hemmung von Apoptose
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
WO1997042319A1 (en) 1996-05-02 1997-11-13 Mochida Pharmaceutical Co., Ltd. NOVEL Fas ANTIGEN DERIVATIVES
ATE273713T1 (de) 1996-10-31 2004-09-15 Mochida Pharm Co Ltd Fas-antagonist für die prophylaxe oder therapie von gvhd
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
DE69810091T2 (de) 1997-02-21 2003-10-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw., Zwijnaarde Verwendung von interleukin-15
AU8784498A (en) * 1997-08-15 1999-03-08 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
IL138626A0 (en) 1998-03-30 2001-10-31 Lilly Co Eli Therapeutic applications of mature flint (mflint) polypeptides or opg3, a member of the receptor superfamily
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
AU4817200A (en) * 1999-05-04 2000-11-17 Human Genome Sciences, Inc. Death domain containing receptor 5
DE19959049A1 (de) 1999-12-07 2001-06-28 Deutsches Krebsforsch Kombination von Verbindungen, welche die biologischen Wirkungen von TNF-alpha und CD95L hemmen
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
PL362324A1 (pl) 2001-02-19 2004-10-18 Merck Patent Gmbh Sztuczne białko o obniżonej immunogeniczności
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DE10122140A1 (de) 2001-05-08 2002-11-28 Apotech Res & Dev Ltd Rekombinante Fusionsproteine und deren Trimere
CN100594935C (zh) * 2001-05-25 2010-03-24 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
DE10160248A1 (de) 2001-12-07 2003-06-26 Alexander Cherkasky Fusionsproteinen enthaltend Fc-Regionen

Also Published As

Publication number Publication date
CY1109536T1 (el) 2014-08-13
US20110305697A1 (en) 2011-12-15
HK1077592A1 (zh) 2006-02-17
US20070269449A1 (en) 2007-11-22
CA2520138A1 (en) 2004-10-07
WO2004085478A2 (en) 2004-10-07
PT1606318E (pt) 2009-11-10
CA2520138C (en) 2017-05-23
ES2327409T3 (es) 2009-10-29
EP1606318A2 (en) 2005-12-21
US8007813B2 (en) 2011-08-30
ATE438662T1 (de) 2009-08-15
AU2004224122A1 (en) 2004-10-07
EP1606319A2 (en) 2005-12-21
WO2004085478A3 (en) 2005-01-06
JP2007533595A (ja) 2007-11-22
EP1606318B1 (en) 2009-08-05
DE602004022390D1 (de) 2009-09-17
JP4741464B2 (ja) 2011-08-03
CA2520254A1 (en) 2004-10-07
JP2007524365A (ja) 2007-08-30
WO2004085479A3 (en) 2004-11-25
DK1606318T3 (da) 2009-11-02
AU2004224123A1 (en) 2004-10-07
SI1606318T1 (sl) 2009-12-31
WO2004085479A2 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
PT1606318E (pt) Proteínas de fusão de fc melhoradas
CY1112787T1 (el) Πολλαπλομερη του υποδοχεα κυτοκινης ζcytor17
PE20001316A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene
BR0212256A (pt) Proteìnas de fusão de transferrina modificadas
DK1047781T3 (da) IL-18-receptorer
DE60333306D1 (de) Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
WO2003034903A3 (en) Psma antibodies and protein multimers
WO2004020404A3 (en) Modified transferin-antibody fusion proteins
DE60234094D1 (de) Spezifische bindungsproteine und ihre verwendung
ES2187954T3 (es) Anticuerpos anti-integrina avb3 antagonistas.
CY1111097T1 (el) Πρωτεϊνη δεσμευσης του υποδοχεα nogo
WO2004020405A3 (en) Modified transferrin fusion proteins
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
UA96122C2 (ru) Антитело или его антигенсвязующий фрагмент, которое специфически связывается с il-22ra, и его применение
WO2003104282A8 (en) Glycoprotein vi - fc fusion protein for treating vascular disorders
EP1476469A4 (en) MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR C5AR LOOPS
NZ547629A (en) Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb
WO2003068977A3 (de) Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden
DK1539221T3 (da) Transferrin-fusionsproteinbiblioteker
WO2005065711A3 (en) Mammalian receptor proteins; related reagents and methods
WO2005025603A3 (en) Methods of using wisp antagonists
WO2002020614A3 (de) Endoglin spezifisches polypeptid, seine herstellung und verwendung
ATE466076T1 (de) Gewebe transglutaminase